Assessment of rAAVrh.74.MHCK7.micro-dystrophin Gene Therapy Using Magnetic Resonance Imaging in Children With Duchenne Muscular Dystrophy

Figures

• 

  Figure 1.. Example Magnetic Resonance (MR) Spectra and Images From Participants in the SRP-9001 Cohort, Natural History Cohort, and Control Cohort Spectra (A) and images (B) of representative participants from the natural history cohort, each participant who received SRP-9001 (participant 1, scan taken 18 months after treatment; participant 2, scans taken 6 and 18 months after treatment; participant 3, scans taken at 12 and 24 months after treatment), and a participant from the control cohort. AM indicates adductor magnus; BFLH, biceps femoris long head; DMD, Duchenne muscular dystrophy; and VL, vastus lateralis.

• 

  Figure 2.. Fat Fraction and Transverse Relaxation Time (qT2) Across Multiple Muscles Based on Quantitative Magnetic Resonance Imaging (MRI) and Spectrometry (MRS) The fat fraction (A) and qT2 (B) were lower in participants in the SRP-9001 cohort across multiple leg muscles compared with those in the natural history cohort. Due to motion artifact, no upper leg qT2 data were available for 1 participant in the SRP-9001 cohort. Although statistical analysis was not performed, group mean data reflected lower quantitative MR biomarker values in the SRP-9001 cohort. Dots indicate individual data points; center lines, means; whiskers, SDs.